Patents Examined by Gregory S. Emch
  • Single domain antibodies capable of modulating BACE activity
    Patent number: 9908943
    Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: March 6, 2018
    Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
  • Antibodies that bind amyloid oligomers
    Patent number: 9895429
    Abstract: Embodiments of the invention are directed to compositions and methods related to immunogenic compositions comprising the amino acid sequence of SEQ ID NO:1 and amyloid oligomer specific antibodies that specifically bind an oligomer comprising such a peptide.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: February 20, 2018
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Rakez Kayed
  • Repair of peripheral nerve injury
    Patent number: 9895399
    Abstract: The invention relates to methods and compositions for maintaining the pro-regenerative capacity of distal nerve segments following nerve injury.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: February 20, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Douglas H. Smith, Kacy D. Cullen, John A. Wolf
  • Human anti-alpha-synuclein antibodies
    Patent number: 9896504
    Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: February 20, 2018
    Assignees: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
  • Compounds and methods for treating pain
    Patent number: 9884911
    Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: February 6, 2018
    Assignee: MEDIMMUNE LIMITED
    Inventors: Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe
  • Modulators of alpha-synuclein toxicity
    Patent number: 9879257
    Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: January 30, 2018
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Susan L. Lindquist, Aaron D. Gitler, Anil Cashikar
  • Methods and compositions with immune therapy for treatment of dementia
    Patent number: 9879076
    Abstract: Novel antibodies, methods and compositions for treatment of a disease which is susceptible to amelioration by the blocking of APP cleavage.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 30, 2018
    Assignee: RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Sarit Samira, Nurit Rachamim, Michael Tal, Ronald Ellis, Idan Rakover, Rom E. Eliaz, Beka Solomon, Timothy David Jones, Francis Joseph Carr, Polina Rabinovich-Toidman, Meital Sooliman
  • Method for determination of amyloid peptides with anti-amyloid antibody
    Patent number: 9863961
    Abstract: The invention relates to the field of immunoassays which allow the detection of A? 17 peptides by virtue of the use of an anti-A? 17 antibody and a kit and method using said antibody. The invention also relates to a method for diagnosing or distinguishing between different stages of a neurodegenerative disease.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: January 9, 2018
    Assignee: ARACLON BIOTECH, S.L.
    Inventor: Manuel Sarasa Barrio
  • Oligomer-specific amyloid beta epitope and antibodies
    Patent number: 9849165
    Abstract: A novel constrained peptide epitope derived from A?, related antibody compositions and methods of use. An isolated antibody that specifically binds to a cyclic peptide comprising the conformational epitope corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric A? is described. An antigenic peptide comprising an epitope having a constrained cyclic configuration, corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric A? is also described. Methods of treating, preventing, and diagnosing Alzheimer's disease are also described.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: December 26, 2017
    Assignee: The University of British Columbia
    Inventor: Neil R. Cashman
  • Promotion of neuronal integration in neural stem cell grafts
    Patent number: 9844572
    Abstract: The invention relates to the treatment of diseases or disorders of the nervous system. In particular, the invention relates to the treatment of diseases or disorders of the nervous system by stem cell therapy, in particular therapy with neural precursor cells. In preferred aspects of the invention, inhibitors of chemoattraction are administered prior to, concomitantly with, or subsequently to the administration of neural precursor cells.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: December 19, 2017
    Assignee: Life & Brain GmbH
    Inventors: Oliver Brüstle, Philipp Koch, Julia Ladewig
  • Use of TRPC6 mRNA levels in peripheral blood cells for early detection/diagnosis of senile dementia
    Patent number: 9790551
    Abstract: The invention relates to the use of TRPC6 mRNA levels in peripheral blood cells for the early detection/diagnosis of senile dementia. Specifically, the present invention provides a classic transient receptor potential channel 6 (TRPC6) gene or protein thereof and the use of same in preparing a reagent or test kit for detecting or diagnosing Alzheimer's disease. The present invention further relates to a polypeptide used to prepare a medicament that treats AD, and relates to a composition of said polypeptide.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: October 17, 2017
    Assignee: Aging Wise Biotechnology, Inc.
    Inventors: Yizheng Wang, Junfeng Wang, Rui Lu
  • Method for achieving desired glial growth factor 2 plasma levels
    Patent number: 9744215
    Abstract: The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: August 29, 2017
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Haesun Kim, Anthony O. Caggiano
  • Compositions and methods for the treatment of sjörgren's syndrome
    Patent number: 9687523
    Abstract: This invention provides a method of inducing a lacrimal acinar cell in a tissue to degrade a secretory vesicle and its content protein or proteins from the trans-Golgi network (TGN) by contacting the cells with an effective amount of an agent that induces autophagy. Also provided is a method for treating a mammal suffering from defective trans-Golgi network-secretory vesicle (TGN-SV) sorting by administering to the mammal an effective amount of an agent that induces autophagy in the tissue having the defective TGN-SV.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: June 27, 2017
    Assignee: University of Southern California
    Inventor: Sarah Hamm-Alvarez
  • Bacteriophage gene 3 protein compositions and use as amyloid binding agents
    Patent number: 9688728
    Abstract: The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: June 27, 2017
    Assignee: PROCLARA BIOSCIENCES, INC.
    Inventors: Rajaraman Krishnan, Richard Fisher
  • Methods for producing enriched populations of human retinal pigment epithelium cells
    Patent number: 9649340
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: May 16, 2017
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Irina V. Klimanskaya, Robert P. Lanza
  • Modalities for the treatment of degenerative diseases of the retina
    Patent number: 9650607
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: May 16, 2017
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Irina V. Klimanskaya, Robert P. Lanza
  • Peptides that bind to amino-truncated amyloid-beta-peptide and use of said peptides
    Patent number: 9611296
    Abstract: Peptides that bind to amino-terminal truncated pEA?3-42, the free glutamic acid residue of which lies in position 3 or 11 in the form of cyclized pyroglutamate. Four oligopeptides were identified using mirror image phage display technology.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: April 4, 2017
    Assignee: Forschungszentrum Juelich GmbH
    Inventors: Dieter Willbold, Susanne Aileen Funke, Yeliz Cinar, Dirk Bartnik, Hans-Ulrich Demuth, Martin Kleinschmidt, Hans-Henning Ludwig
  • Amyloid beta peptides as therapy for multiple sclerosis
    Patent number: 9610326
    Abstract: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an amyloid beta peptide, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: April 4, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Lawrence Steinman, Jacqueline Grant
  • Human anti-tau antibodies
    Patent number: 9605059
    Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: March 28, 2017
    Assignees: Biogen International Neuroscience GmbH, University of Zürich
    Inventors: Roger Nitsch, Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Christoph Hock
  • Peptides for the treatment and early diagnosis of Alzheimer's disease and other tauopathies
    Patent number: 9580469
    Abstract: The present invention relates to novel tau protein aggregate-binding peptides, homologs, fragments, parts and polymers thereof and to the use thereof.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: February 28, 2017
    Assignee: Forschungszentrum Juelich GmbH
    Inventors: Susanne Aileen Funke, Dieter Willbold